FDA to Review Peptide Access Rules in July Hearing

The FDA will convene an advisory panel on July 23 and 24 to decide whether compounding pharmacies can manufacture seven peptides the agency removed from its approved list in 2023. The decision follows pressure from Health Secretary Robert F. Kennedy Jr., who has advocated for broader access to the drugs.

The FDA announced the panel meetings on Wednesday. The July session will focus on whether to restore seven peptides to the list of substances compounding pharmacies are permitted to produce. A second panel meeting, scheduled before the end of February 2027, will address five additional peptides that were also removed in 2023.

The 2023 delisting affected 19 peptides total. Compounding pharmacies currently cannot legally manufacture most of these substances, though they remain available through other channels and have gained popularity through online promotion and influencer endorsement.

Kennedy stated in a February podcast appearance with Joe Rogan that he wanted to increase access to peptides. His position as Health Secretary gives him influence over FDA policy direction, though the agency maintains formal independence in regulatory decisions. The advisory panel's recommendation will inform the FDA's final determination on each peptide.

Limited clinical data exists on the safety and effectiveness of many peptide products currently in circulation. The compounds are marketed for various health purposes, but their therapeutic claims often lack rigorous scientific support. The panel will likely examine available evidence during its deliberations.

Context

The 2023 delisting represented a significant tightening of compounding pharmacy rules. Compounding pharmacies traditionally operate under less stringent oversight than manufacturers of FDA-approved drugs, producing customized medications for individual patients. The 2023 action reflected FDA concerns about quality control and unsubstantiated claims in the peptide market.

Peptides—short chains of amino acids—have become a major component of the unregulated supplement and compounding pharmacy market. The category includes substances marketed for muscle growth, weight loss, and anti-aging, often promoted through social media and celebrity endorsement. Unlike FDA-approved drugs, compounded peptides do not require proof of efficacy before reaching consumers.

The advisory panel structure allows the FDA to gather expert input before making regulatory decisions, but panels do not have binding authority. The agency can accept or reject panel recommendations, though it typically aligns with expert consensus on safety and efficacy matters.

What's Next

The July panel meeting will be the first public forum where the FDA formally examines the scientific case for restoring peptide access. The outcome will likely set a precedent for how aggressively the agency pursues compounding pharmacy restrictions in other categories. If the panel recommends restoration, the FDA could approve the change by late 2026, potentially expanding the peptide market before the second panel convenes in early 2027.

Kennedy's involvement signals that peptide policy will remain a priority within the health agency. Any FDA decision to restore peptide access could prompt scrutiny from medical groups concerned about unproven therapies, as well as from consumer advocates focused on product safety.